Overview

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
0
Participant gender:
Male
Summary
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the widely studied 68Ga-PSMA-617. This pilot study was prospectively designed to evaluate the early dynamic distribution of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-617 in the same group of prostate cancer patients.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Edetic Acid
Gallium 68 PSMA-11
Criteria
Inclusion Criteria:

- confirmed treated or untreated prostate cancer patients;

- 68Ga-PSMA617 and 68Ga-P16-093 PET/CT within two consecutive days;

- signed written consent.

Exclusion Criteria:

- known allergy against PSMA;

- any medical condition that in the opinion of the investigator may significantly
interfere with study compliance.